Sotan 75 Mg/ 150 Mg/ 300 Mg 75 mg/ 150 mg/ 300 mg TABLETS
PDF Leaflet Revision Date: 26 February 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of essential hypertension and diabetic nephropathy in Type 2 diabetes.
Dosage (summary)
Initial: 150 mg once daily; may increase to 300 mg if needed.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; discontinue if pregnancy occurs.
Key Drug Interactions
- Potassium-sparing diuretics
- Lithium
- NSAIDs
Contraindications
- Hypersensitivity to irbesartan
- History of angioedema
- Severe renal impairment
- Bilateral renal artery stenosis
Common side effects
- Dizziness
- Nausea
- Fatigue
- Hyperkalaemia
Counselling Points
- Take with or without food
- Monitor blood pressure regularly
- Avoid potassium supplements
Serious warnings
- Risk of hypotension in volume-depleted patients
- Monitor for hyperkalaemia
Important Disclaimer
The Sotan 75 Mg/ 150 Mg/ 300 Mg 75 mg/ 150 mg/ 300 mg TABLETS professional information leaflet below is the property of Aurogen South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
